XML 61 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Revenue Recognition (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
item
agreement
Dec. 31, 2021
USD ($)
Disaggregation of Product Revenue    
Number of distribution agreements | agreement 2  
Mytesi    
Disaggregation of Product Revenue    
Product revenue $ 11,700,000 $ 4,300,000
Number of specialty pharmacies. | item 5  
Mytesi | Specialty Pharmacies    
Disaggregation of Product Revenue    
Product revenue $ 10,300,000 993,000
Canalevia-CA1    
Disaggregation of Product Revenue    
Product revenue 167,000 0
Neonorm    
Disaggregation of Product Revenue    
Product revenue $ 48,000 $ 62,000